SIRT1 and diffuse large B-cell lymphoma: Given the very high potential of HSP90/SIRT1 inhibitors for combinations with additional chemotherapeutics, these studies warrant further investigations of HSP90/SIRT1 pathway inhibitor combinations in OxPhos-dependent DLBCL models.